Michelle Noto
Family · Covina, CANPI 1427396878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$735
- AbbVie$543
- Amgen$477
- Merck$429
- Boehringer Ingelheim$381
- Lilly USA, LLC$359
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,443100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $735 |
| AbbVie(2 entities) | 22 | $543 |
| Amgen(2 entities) | 20 | $477 |
| Merck | 16 | $429 |
| Boehringer Ingelheim | 14 | $381 |
| Lilly USA, LLC | 15 | $359 |
| AstraZeneca | 17 | $359 |
| GSK | 8 | $301 |
| Pfizer | 12 | $278 |
| Johnson & Johnson | 11 | $220 |
| Astellas Pharma US Inc | 7 | $179 |
| Abbott | 8 | $166 |
| Novartis | 6 | $129 |
| Bayer | 5 | $118 |
| Sanofi-aventis U.S. LLC | 7 | $118 |
| Sumitomo Pharma America, Inc. | 4 | $113 |
| Edwards Lifesciences | 1 | $52 |
| Exact Sciences | 2 | $50 |
| Amarin Pharma, Inc. | 2 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Phadia US Inc. | 2 | $34 |
| Mayne Pharma Commercial LLC | 1 | $32 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Averitas Pharma Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$122
How this compares
$5,443 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $96,344 |
| JardianceEmpagliflozin | 70 | $87,672 |
| MounjaroTirzepatide | 45 | $63,304 |
| EliquisApixaban | 56 | $58,357 |
| JanuviaSitagliptin Phosphate | 30 | $40,096 |
| TrulicityDulaglutide | 18 | $33,398 |
| MyrbetriqMirabegron | 28 | $32,034 |
| LinzessLinaclotide | 23 | $29,213 |
| RybelsusSemaglutide | 13 | $28,535 |
| XareltoRivaroxaban | 25 | $27,998 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $24,102 |
| GemtesaVibegron | 17 | $21,986 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $21,863 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $18,156 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $17,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $735 | $124,87963 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $381 | $105,58283 claims |
| Lilly USA, LLCMounjaro, Trulicity | $359 | $96,70263 claims |
| MerckJanuvia, Janumet, Janumet Xr | $429 | $76,94966 claims |
| PfizerEliquis | $278 | $58,35756 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $32,03428 claims |
| AbbVieLinzess, Synthroid | $543 | $30,32744 claims |
| Johnson & JohnsonXarelto | $220 | $27,99825 claims |
| GSKTrelegy Ellipta | $301 | $24,10219 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $113 | $21,98617 claims |
| AstraZenecaBreztri Aerosphere | $359 | $18,15620 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $24 | $15,69711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Covina
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.